Telix Pharmaceuticals

🇦🇺 This Week in Australian Startups #179, 26th September 2026

Weekly roundup recording a dozen raises and acquisitions, Firmus's scheduled float, a new $50m venture fund, a founder share sale, grant winners, an accelerator intake, and an AI agent's government breach.

Also Dynamic Business·DealStreetAsia·This Week in Australian Startups·Dealroom·ABC News Technology

Telix Pharmaceuticals strikes $3.3b merger with German radioisotope giant ITM

Melbourne's Telix Pharmaceuticals will merge with German radioisotope maker ITM in a deal worth as much as $3.3 billion, keeping about 76 per cent ownership with existing Telix shareholders once completed.

Also Biotech Dispatch

Telix bets $1.7B on ITM to build radiopharma powerhouse

Australian-listed Telix is buying German radioisotope supplier ITM in a $1.65 billion deal with contingent milestone payments, creating an end-to-end radiopharmaceutical business.

FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug

Telix Pharmaceuticals has gained US regulatory clearance for its glioma imaging agent Pixclara, a world first, and is now studying the compound in late-stage trials for brain metastases.

Guided nuclear missile for cancer: Telix prepares for Nasdaq IPO

Telix, an ASX-listed radiopharmaceutical maker headquartered in Melbourne, is preparing a dual US listing; the piece also covers revenue growth, cancer trial results and recalls its 2017 float.

Manufacturing news briefs – stories you might have missed

Roundup of Australian manufacturing news: Matrak closes a Series A, Queensland Pacific Metals receives an R&D tax refund, ARENA funds a household energy trial, Ampcontrol appoints a transformation chief, plus policy and launch briefs.

Also @AuManufacturing

Starpharma, UQ target new radiopharmaceuticals

Starpharma, two universities, Telix, Clarity and CSIRO launch an ARC-backed radiopharmaceutical research hub with a government grant and industry funding.